- Translational considerations for cancer nanomedicine
[作者：Stern, ST; Hall, JB; Yu, LL; Wood, LJ; Paciotti, GF; Tamarkin, L; Long, SE; McNeil, SE,期刊：Journal of controlled release, 页码：164-174 , 文章类型： Proceedings Paper，,卷期：2010年146-2]
- There are many important considerations during preclinical development of cancer nanomedicines, including: 1) unique aspects of animal study design; 2) the difficulties in evaluating biological potency, especially for co...
- Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: The challenges ahead
[作者：Moghimi, SM; Andersen, AJ; Hashemi, SH; Lettiero, B; Ahmadvand, D; Hunter, AC; Andresen, TL; Hamad, I; Szebeni, J,期刊：Journal of controlled release, 页码：175-181 , 文章类型： Proceedings Paper，,卷期：2010年146-2]
- Since their introduction, poly(ethylene glycol)-phospholipid (PEG-PL) conjugates have found many applications in design and engineering of nanosized delivery systems for controlled delivery of pharmaceuticals especially ...
- Physicochemical parameters affecting liposomal bisphosphonates bioactivity for restenosis therapy: Internalization, cell inhibition, activation of cytokines and complement, and mechanism of cell death
[作者：Epstein-Barash, H; Gutman, D; Markovsky, E; Mishan-Eisenberg, G; Koroukhov, N; Szebeni, J; Golomb, G,期刊：Journal of controlled release, 页码：182-195 , 文章类型： Proceedings Paper，,卷期：2010年146-2]
- Partial inactivation and transient depletion of monocytes/macrophages by liposomal bisphosphonates (LIP-Bps) is widely experimented in various inflammatory disorders including restenosis. Previous studies on activation o...
- Flow and adhesion of drug carriers in blood vessels depend on their shape: A study using model synthetic microvascular networks
[作者：Doshi, N; Prabhakarpandian, B; Rea-Ramsey, A; Pant, K; Sundaram, S; Mitragotri, S,期刊：Journal of controlled release, 页码：196-200 , 文章类型： Proceedings Paper，,卷期：2010年146-2]
- Development of novel carriers and optimization of their design parameters has led to significant advances in the field of targeted drug delivery. Since carrier shape has recently been recognized as an important design pa...
- A study of drug release from homogeneous PLGA microstructures
[作者：Acharya, G; Shin, CS; Vedantham, K; McDermott, M; Rish, T; Hansen, K; Fu, YR; Park, K,期刊：Journal of controlled release, 页码：201-206 , 文章类型： Proceedings Paper，,卷期：2010年146-2]
- The hydrogel template method was used to fabricate homogeneous drug-PLGA microparticles. Four drugs (felodipine, risperidone, progesterone, and paclitaxel) were loaded into the PLGA particles with the homogeneous size of...
- Temperature-induced gel formation of core/shell nanoparticles for the regeneration of ischemic heart
[作者：Oh, KS; Song, JY; Yoon, SJ; Park, Y; Kim, D; Yuk, SH,期刊：Journal of controlled release, 页码：207-211 , 文章类型： Proceedings Paper，,卷期：2010年146-2]
- Vascular endothelial growth factor (VEGF)-loaded core/shell nanoparticles were prepared and their gelation behavior in response to temperature was characterized for the regeneration of ischemic heart. The core is compose...
- Localized doxorubicin chemotherapy with a biopolymeric nanocarrier improves survival and reduces toxicity in xenografts of human breast cancer
[作者：Cai, SA; Thati, S; Bagby, TR; Diab, HM; Davies, NM; Cohen, MS; Forrest, ML,期刊：Journal of controlled release, 页码：212-218 , 文章类型： Proceedings Paper，,卷期：2010年146-2]
- Patients with metastatic breast cancer have a five-year survival rate of 27% compared to 98% for localized cancer, and the presence of even a few cancer cells in lymph nodes, known as isolated tumor cells or nanometastas...
- Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring
[作者：Kim, K; Kim, JH; Park, H; Kim, YS; Park, K; Nam, H; Lee, S; Park, JH; Park, RW; Kim, IS; Choi, K; Kim, SY; Park, K; Kwon, IC,期刊：Journal of controlled release, 页码：219-227 , 文章类型： Proceedings Paper，,卷期：2010年146-2]
- Theragnostic multifunctional nanoparticles hold great promise in simultaneous diagnosis of disease, targeted drug delivery with minimal toxicity, and monitoring of treatment. One of the current challenges in cancer treat...
- Telomerase as emerging target to fight cancer - Opportunities and challenges for nanomedicine
[作者：Philippi, C; Loretz, B; Schaefer, UF; Lehr, CM,期刊：Journal of controlled release, 页码：228-240 , 文章类型： Proceedings Paper，,卷期：2010年146-2]
- Telomerase as an enzyme is responsible for the renewal of the chromosomal ends, the so-called telomeres. By preventing them from shortening with each cell cycle, telomerase is able to inhibit cellular senescence and apop...
|